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increased to $50,000 per QALY at a cost of $13.70 per day
for high-dose dabigatran, but remained <$85,000 per QALY
over the full range of model inputs evaluated. Cost-effective-
ness of high-dose dabigatran improved with increasing risk
for stroke and intracranial hemorrhage.
Conclusions: In patients ages ≥65 years with nonvalvular AF
at increased risk for stroke, dabigatran may be a cost-effec-
tive alternative to warfarin.
Perspective: The base-case analysis estimated a cost that was
within a range generally considered cost-effective. For patients
at higher risk for ischemic stroke or intracranial hemorrhage,
including those with CHADS2 scores of ≥2, the cost-effec-
tiveness for high-dose dabigatran compared with warfarin
improved. The results of this analysis were derived from a sin-
gle clinical trial and could change if future effectiveness
studies provide alternative estimates for bleeding risk and
stroke reduction.   
Summary written by: Debabrata Mukherjee, MD
Dabigatran Versus Warfarin in Patients With Atrial
Fibrillation: An Analysis of Patients Undergoing
Cardioversion
Nagarakanti R, Ezekowitz MD, Oldgren J, et al.
Circulation 2011;123:131–136.
Study Question: Is anticoagulation with dabigatran adequate
for stroke prevention in the setting of cardioversion of atrial
fibrillation (AF)? 
Methods: This was a post-hoc analysis of 1,983 cardioversions
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Cost-Effectiveness of Dabigatran Compared With
Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman JV, Zhu RP, Owens DK, et al.
Ann Intern Med 2011;154:1–11.
Study Question: What is the quality-adjusted survival, costs,
and cost-effectiveness of dabigatran compared with
adjusted-dose warfarin for preventing ischemic stroke in
patients with nonvalvular atrial fibrillation (AF)?   
Methods: The study used a Markov decision model using the
RE-LY trial and other anticoagulation studies. The study
population consisted of patients ages ≥65 years with non–
valvular AF and risk factors for stroke (CHADS2 score ≥1)
and no contraindications to anticoagulation. Warfarin anti-
coagulation (target international normalized ratio, 2.0-3.0)
was compared with dabigatran 110 mg twice daily (low
dose) and dabigatran 150 mg twice daily (high dose), and
quality-adjusted life-years (QALYs), costs (in 2008 US dol-
lars), and incremental cost-effectiveness ratios were analyzed.
Results: The quality-adjusted life expectancy was 10.28
QALYs with warfarin, 10.70 with low-dose dabigatran, and
10.84 with high-dose dabigatran. Total costs were $143,193
for warfarin, $164,576 for low-dose, and $168,398 for high-
dose dabigatran. The incremental cost-effectiveness ratios
compared with warfarin were $51,229 per QALY for low-
dose and $45,372 for high-dose dabigatran. The model was
sensitive to the cost of dabigatran, but relatively insensitive to
other model inputs. The incremental cost-effectiveness ratio
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1.005-1.029 for a BMI increase of 1 kg/m2; 95% CI 1.024-
1.155 for a BMI increase of 5 kg/m2; 95% CI 1.049-1.334 for
a BMI increase of 10 kg/m2; p = 0.006 for each). Increased
BMI was also associated with a higher likelihood of being in
AF on follow-up (95% CI 1.002-1.038 per 1 kg/m2 increased
BMI, p = 0.028; 95% CI 1.011-1.205 per 5 kg/m2 increased
BMI, p = 0.028; 95% CI 1.021-1.452 per 10 kg/m2 increased
BMI, p = 0.028). In a multivariate analysis, left atrial size but
not BMI was an independent predictor of AF recurrence and
AF burden. Because left atrial size was correlated with BMI,
the effect of BMI on AF can likely be explained by greater left
atrial size in subjects with higher BMIs.
Conclusions: Obesity is associated with a higher incidence of
recurrent AF and greater AF burden.
Perspective: This informative study suggests that BMI is
associated with both recurrence and burden of AF. An
important next question to address is whether weight loss
would result in reductions in AF.  
Summary written by: Elizabeth A. Jackson, MD
Cardiovascular Surgery
Secondary Prevention After Coronary Artery
Bypass Graft Surgery: Findings of a National
Randomized Controlled Trial and Sustained
Society-Led Incorporation Into Practice 
Williams JB, Delong ER, Peterson ED, et al., on Behalf of the
Society of Thoracic Surgeons and the National Cardiac Database.
Circulation 2011;123:39–45.
Study Question: Can a low-intensity continuous quality
improvement intervention be used to enhance secondary
prevention adherence after coronary artery bypass graft sur-
gery (CABG)?     
Methods: A total of 458 hospitals participating in the Society
of Thoracic Surgeons National Cardiac Database and treat-
ing 361,328 patients undergoing isolated CABG were
randomized to either a control or an intervention group.
The intervention group received continuous quality
improvement materials designed to influence the prescrip-
tion of the secondary prevention medications at discharge.
The primary outcome measure was discharge prescription
rates of the targeted secondary prevention medications at
intervention versus control sites, assessed by measuring pre-
and post-intervention site differences.
Results: Mean age was 64 years, 75% were men, 34% diabetics,
75% hypertensive, and 50% of CABGs were elective.
Prerandomization treatment patterns and baseline data were
similar in the control (n = 234) and treatment (n = 224) sites.
The mean change in use of treatments was 2.9% versus 4.2%
for aspirin, 9.7% versus 12.2% for beta-blockers, 6.4% vs.
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in 1,270 patients enrolled in the RE-LY trial, in which
18,113 patients with AF were randomly assigned to anticoag-
ulation with warfarin, dabigatran 110 mg twice daily (D110),
or dabigatran 150 mg twice daily (D150). The number of car-
dioversions in the three groups ranged from 647 to 672, and
86% of the cardioversions were electrical. A transesophageal
echocardiogram (TEE) was performed before cardioversion in
13%, 26%, and 24% of patients in the warfarin, D110, and
D150 groups, respectively. The primary outcomes were stroke,
systemic embolism, and major bleeding episodes within 30
days of cardioversion.
Results: The stroke/systemic embolism rate did not differ sig-
nificantly between the three groups (0.6%, 0.8%, 0.3% in the
warfarin, D110, and D150 groups, respectively). The
stroke/embolism rate did not differ between patients with
and without a TEE in any of the groups. Rates of major
bleeding also did not differ significantly between the groups
(0.6%, 1.7%, and 0.6% in the warfarin, D110, and D150
groups, respectively).
Conclusions: The risks of post-cardioversion stroke and major
bleeding are similar with warfarin and dabigatran, whether
or not a TEE is performed pre-cardioversion.
Perspective: The results indicate that dabigatran is a reasonable
alternative to warfarin for stroke prevention post-cardiover-
sion. A possible advantage of warfarin is that therapeutic
anticoagulation can be verified by measuring the international
normalized ratio. With dabigatran, confirmation of anticoag-
ulation with a laboratory test is not feasible and one must rely
on patients stating that they took dabigatran as prescribed.   
Summary written by: Fred Morady, MD
Relation of Obesity to Recurrence Rate and
Burden of Atrial Fibrillation
Guglin M, Maradia K, Chen R, Curtis AB.
Am J Cardiol 2011;Jan 3:[Epub ahead of print].
Study Question: Does obesity increase the risk for recurrent
atrial fibrillation (AF)?   
Methods: A limited access data set from the AFFIRM trial
was used for this analysis. Of the 4,060 patients enrolled in
AFFIRM, 1,542 were excluded for missing data on body
mass index (BMI). Among the 2,518 patients, data on
22,753 follow-up visits and 1,094 cardioversions were avail-
able. The primary outcomes were AF recurrence
(cardioversions were a surrogate marker of recurrence) and
AF burden (defined as the number of follow-up visits in
which the patient was in AF).
Results: BMI, left atrial size, age, and history of hypertension
were independently associated with higher AF burden.
Patients with a higher BMI were associated with a higher
number of cardioversions (95% confidence interval [CI]
metabolic syndrome and low HDL cholesterol levels treated
with pioglitazone, but not in patients with hypercholes-
terolemia treated with statins.  
Conclusions: Cholesterol efflux capacity from macrophages, a
metric of HDL function, has a strong inverse association with
both CIMT and the likelihood of angiographic CAD, inde-
pendently of the HDL cholesterol level.
Perspective: This study quantified cholesterol efflux capacity by
incubating macrophages with serum from the study partici-
pants depleted of apo B. Because this property of HDL was
largely independent of HDL cholesterol levels and independ-
ently predicted presence of atherosclerosis (in this
cross-sectional study), these results confirm that methods to
analyze HDL function are needed and will be helpful in the
evaluation and design of therapeutic strategies affecting HDL.  
Summary written by: Daniel T. Eitzman, MD
Medication Adherence Leads to Lower Health Care
Use and Costs Despite Increased Drug Spending 
Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA.
Health Affairs 2011;30:91–99.
Study Question: Does medication adherence lead to lower
health care costs despite increase in drug costs? 
Methods: Data were extracted from integrated pharmacy and
medical administrative claims data from the CVS Caremark
data on people who had continuous health insurance cover-
age sponsored by one of nine US employers from January 1,
2005, through June 30, 2008. Data were analyzed for four
chronic vascular conditions: congestive heart failure (CHF),
hypertension, diabetes, and dyslipidemia. Analysis included
annual numbers of inpatient hospital days, emergency
department visits, and outpatient physician visits, and three
measures of health services cost: annual pharmacy, medical,
and total health care costs. Adherence was defined as a
medication possession ratio of ≥0.80, and any less was
defined as nonadherent.
Results: There were ~135,000 patients, and groups were rela-
tively balanced by gender. CHF patients tended to be older
(average 77 years) than patients with the other three condi-
tions (averages 65-68 years).  Adherence rates varied from
34% to 51%. Total health care costs per patient per year aver-
aged $39,076 for CHF, $14,813 for hypertension, $17,955
for diabetes, and $12,688 for dyslipidemia. Total outpatient
pharmacy costs ranged from $2,867 to $3,780 per patient per
year. Adherence was associated with significantly lower
annual inpatient hospital days (1.18 fewer days for dyslipi-
demia to 5.72 fewer days for CHF). Annual emergency
department visits were minimally lower and doctor visits were
higher in the adherent cohort. Adherence reduced average
annual medical spending by $8,881 in CHF, $4,337 in
hypertension, $4,413 in diabetes, and $1,860 in dyslipidemia.
13.1% for angiotensin-converting enzyme inhibitors, and
13.1% vs. 15.75% for lipid treatment, and for all versus not all,
12.1% versus 16.7%. Individual medication use and composite
adherence increased over 24 months in both groups, with a
markedly more rapid rate of adherence uptake among the
intervention hospitals and a statistically significant therapy
hazard ratio in the intervention versus control group for all
four secondary prevention medications. Improvement was lim-
ited to the nonacademic centers.
Conclusions: Provider-led, low-intensity continuous quality
improvement efforts can improve the adoption of care
processes into national practice within the context of a med-
ical specialty society infrastructure. These findings have led
to the incorporation of study outcome metrics into a medical
society rating system for ongoing quality improvement.
Perspective: The important message is that major impacts on
outcome can result from relatively simple encouragements to
cardiac surgeons. Opportunities to increase evidence-based
care include a pharmacy specialist, nurse practitioner, or car-
diology consultation prior to discharge of cardiac surgical
patients with the responsibility of selecting which of the
‘evidence-based treatments’ is indicated, and importantly,
the optimal dosing schedule, drug information, and needed
follow-up to assure adherence.  
Summary written by: Melvyn Rubenfire, MD
General Cardiology
Cholesterol Efflux Capacity, High-Density
Lipoprotein Function, and Atherosclerosis
Khera AV, Cuchel M, de la Llera-Moya M, et al.
N Engl J Med 2011;364:127–135.
Study Question: Does cholesterol efflux capacity from
macrophages predict atherosclerosis burden independently of
high-density lipoprotein (HDL) levels?  
Methods: Cholesterol efflux capacity was measured in 203
healthy volunteers who underwent assessment of carotid
artery intima-media thickness (CIMT), 442 patients with
angiographically confirmed coronary artery disease (CAD),
and 351 patients without. 
Results: Levels of HDL cholesterol and apolipoprotein (apo)
A-I were significant determinants of cholesterol efflux capac-
ity, but accounted for less than 40% of the observed variation.
An inverse relationship was noted between efflux capacity and
CIMT before and after adjustment for HDL cholesterol level.
Furthermore, efflux capacity was a strong inverse predictor of
CAD status (p < 0.001). This relationship remained signifi-
cant, after additional adjustment for the HDL cholesterol
level (p = 0.002) or apo A-I level (p = 0.002). Additional stud-
ies showed enhanced efflux capacity in patients with the
JACC, Vol. 57, No. 9, 2011
March 1, 2011:1045–52
Eagle, Cannon 1047
Scanning the Literature
Benefit-cost ratios ranged from 2:1 for adults under age 65
with dyslipidemia, to more than 13:1 for older patients with
hypertension.
Conclusions: In light of the Affordable Care Act’s expansion
of access to medical care, policy makers must now search for
ways to improve health outcomes while reducing spending.
Given the findings in the CVS Caremark study, plan spon-
sors, government payers, and patients should consider
participating in programs that improve medication adher-
ence, as long as intervention costs do not exceed the
estimated health care savings.
Perspective: The findings support the thesis that medical care
can be cost-effective, but requires adherence to avoid waste.
Among the opportunities to increase adherence and reduce
cost include electronic monitoring/tracking with regular
physician feedback, physician incentive for adherence, and
nurse- or pharmacist-led counseling. It would have been of
value to see the threshold of adherence that is associated with
maximal and minimal benefit-cost ratios for each condition.  
Summary written by: Melvyn Rubenfire, MD
Meta-Analysis of Randomized Trials of Glycoprotein
IIb/IIIa Inhibitors in High-Risk Acute Coronary
Syndromes Patients Undergoing Invasive Strategy 
De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H.
Am J Cardiol 2011;107:198–203. 
Study Question: What is the comparative effectiveness of a
strategy of upstream administration of glycoprotein (GP)
IIb/IIIa inhibitors, aimed at cooling the culprit coronary
plaque before angioplasty, to a strategy of downstream selec-
tive administration of such drugs?
Methods: The investigators obtained results from all random-
ized trials on this issue. A literature search of electronic
databases from January 1990 to March 2010, used the fol-
lowing key words: “randomized trial,” “myocardial
infarction,” “ACS,” “coronary angioplasty,” “upstream,”
“downstream,” “GP IIb/IIIa inhibitors,” “abciximab,”
“tirofiban,” and “eptifibatide.” Primary and secondary clini-
cal endpoints were mortality and myocardial infarction at 30
days, respectively. Major bleeding complications were
assessed as a safety endpoint.
Results: Seven randomized trials were included in the meta-
analysis, involving 19,929 patients (9,981 or 50.0% in the
upstream GP IIb/IIIa inhibitors group and 9,948 or 50% in
the downstream group). Upstream GP IIb/IIIa inhibitors
did not decrease 30-day mortality (2.0% vs. 2.0%, p = 0.84)
or recurrence of myocardial infarction (7.0% vs. 7.6%, p =
0.11), but were associated with higher risk of major bleeding
complications (1.8% vs. 1.3%, p = 0.0002). 
Conclusions: In high-risk patients with acute coronary syn-
drome (ACS) undergoing an early invasive strategy,
upstream administration of GP IIb/IIIa inhibitors does not
improve clinical outcome compared to a downstream selec-
tive administration.
Perspective: In addition to not providing benefits for death and
myocardial infarction, this upstream administration strategy is
associated with a significantly higher risk of major bleeding
complications. Increased use of more powerful P2Y12
inhibitors will probably further decrease potential benefits from
unselected upstream administration of GP IIb/IIIa inhibitors.
Based on available evidence, unselected upstream administra-
tion of GP IIb/IIIa inhibitors should be discouraged.  
Summary written by: Debabrata Mukherjee, MD
Heart Failure/Transplant
Exercise Training in Heart Failure: Practical
Guidance 
Conraads VM, Beckers PJ.
Heart 2010;96:2025–2031.
Perspective: This review discusses the clinical application and
research supporting the use of exercise training in heart fail-
ure (HF). The following are 10 points to remember: 
1: Exercise training in HF can improve aerobic capacity by
15-30%.
2: Exercise capacity is assessed through peak oxygen consump-
tion (pVO2) measurements obtained during cardiopulmonary
stress testing (CPET). pVO2 is aberrant in HF due to reduced
cardiac output and impaired capacity of the periphery to
extract O2.  
3: During maximal exercise, lactate is produced, which leads
to CO2 generation and a compensatory rise in minute venti-
lation. Ventilatory anaerobic threshold occurs when minute
ventilation increases exponentially to VO2. Exercise training
delays the occurrence of anaerobic threshold, which may
reduce dyspnea with exertion in HF.
4: CPET protocols expected to yield an exercise duration of 8-
12 minutes should be selected to ensure adequate results. In
general, heart failure medications should not be adjusted or
held prior to testing. 
5: Initial exercise tolerance (pVO2) measured at the baseline
CPET should be used to formulate an exercise prescription
(duration and intensity).  
6: The 6-minute walk test does not substitute for information
obtained from the CPET. Estimating pVO2 from stress tests
that do not measure gas exchange is often erroneous in HF. 
7: Muscle wasting is an important contributor to poor func-
tional status in HF. Strength training should be incorporated
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Perspective: Extrapolating the results from this registry analy-
sis to others, this study suggests that large patient registries
in heart failure can accurately reflect patients cared for in the
general population. The large patient numbers yielded highly
statistically significant p values when assessing mortality and
readmissions, but these are unlikely to be clinically relevant.
Overall, this was a relatively ill group, with a mortality of
43% at 1 year.  
Summary written by: Jennifer Ann Cowger, MD
High-Sensitivity ST2 for Prediction of Adverse
Outcomes in Chronic Heart Failure
Ky B, French F, McCloskey K, et al.
Circ Heart Fail 2010;Dec 22:[Epub ahead of print].
Study Question: The ST2 receptor is a member of the toll-
like/interleukin-1 receptor family and may be involved in
cardioprotective stress-response signaling. Soluble ST2 is pre-
dictive of adverse outcomes in acute heart failure (HF), but
does ST2 predict chronic HF outcomes?  
Methods: The association between ST2 levels and transplant-
free survival in 1,141 subjects with chronic HF was
evaluated. Cox hazard ratios were calculated, and the predic-
tive ability of ST2 was compared with N-terminal portion of
probrain natriuretic peptide (NT-proBNP) and the Seattle
Heart Failure model (SHFM) using receiver operating char-
acteristic (ROC) curves.
Results: The mean ± standard deviation patient age was 56 ± 14
years, 67% were male, and 87% had systolic HF with a mean
left ventricular ejection fraction of 32 ± 17%. Median NT-
proBNP levels were 567 and the mean SHFM score was 0.25
± 1.0. Over 2.78 years of follow-up, there were 160 deaths and
107 transplantations. Compared with the lowest tertile,
patients in the highest ST2 tertile (ST2 >36.2 ng/ml) had a
3.2 higher unadjusted hazard ratio for death/transplantation.
On a continuous scale, each doubling of ST2 was associated
with an adjusted 40-50% increased odds of death/transplanta-
tion. The area under the ROC curve for ST2 in predicting
death/transplantation was 0.75, which was similar to that of
NT-proBNP (AUC = 0.77; p = 0.24), but inferior to the
SHFM (AUC = 0.81; p = 0.014). The addition of ST2 and
NT-proBNP to the SHFM improved the risk stratification of
14.9% of patients compared with the SHFM alone (p =
0.017), but this effect was not noted when ST2 was added to a
model containing the SHFM and NT-proBNP. 
Conclusions: ST2 is prognostic of poor outcome in patients
with chronic HF.
Perspective: Prognosticating outcome in HF is important for
patient and family education as well as for determining optimal
timing for transplant or left ventricular assist device (LVAD)
in those eligible. With the known limitations of the SHFM in
into the HF exercise regimen, which improves submaximal
exercise tolerance and reduces cardiovascular load by improv-
ing muscular efficiency. 
8: Exercise training has been shown to reduce natriuretic pep-
tide and catecholamine concentrations as well as markers of
oxidative stress, inflammation, and endothelial dysfunction,
and increases cardiac output. 
9: In the largest exercise training trial in HF to date (HF-
ACTION), the adjusted composite endpoint of mortality and
hospitalization was reduced by 11%.
10: Patient adherence to long-term exercise programs is poor,
and training effects wane as little as 2-3 weeks after cessation
of exercise.
Summary written by: Jennifer Ann Cowger, MD
Generalizability and Longitudinal Outcomes of a
National Heart Failure Clinical Registry:
Comparison of Acute Decompensated Heart
Failure National Registry (ADHERE) and Non-
ADHERE Medicare Beneficiaries 
Kociol RD, Hammill BG, Fonarow GC, et al.
Am Heart J 2010;160:885–892. 
Study Question: Can clinical registry data be generalized to the
general population of interest? 
Methods: Elderly patients enrolled into the Acute
Decompensated Heart Failure National Registry (ADHERE)
(ages ≥65 years with discharge diagnosis of heart failure
between 2001-2006) were matched to records to fee-for-ser-
vice Medicare claims data, forming two groups: ADHERE
patients linked to Medicare claims and those not linked.
ADHERE Medicare linked patients were also compared to a
group of Medicare patients not enrolled into ADHERE. The
primary outcome of interest was the cumulative incidence of
mortality, and readmission within each group was assessed via
Kaplan-Meier analysis.
Results: There were 104,808 admissions (82,074 elderly
patients) in the ADHERE registry matched to Medicare
claims. Mortality in ADHERE patients linked (4.5%, n =
4,704) and not linked (4.5%, n = 1,389) to Medicare was
similar (p = 0.92). In the Medicare groups, patients enrolled
into ADHERE had statistically lower unadjusted mortality
(4.4% in-hospital and 36% 1-year) than those not enrolled
(4.9% in-hospital and 38% 1-year, p < 0.001). Likewise,
readmissions were fewer in the ADHERE Medicare
patients (42.6% at 1 year vs. 43.4%, p < 0.001). ADHERE
hospitals were more likely to be teaching hospitals with
higher heart failure volumes. 
Conclusions: Elderly patients in the ADHERE registry are sim-
ilar to Medicare beneficiaries hospitalized with heart failure.
JACC, Vol. 57, No. 9, 2011
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cohorts with very advanced HF, the addition of the ST2 to
the SHFM may improve HF prognostication and candidate
selection for transplant/LVAD. ST2 may be especially useful
for those patients in whom NT-proBNP may not accurately
reflect HF severity (e.g., renal failure, obesity).  
Summary written by: Jennifer Ann Cowger, MD
Relative Merits of Left Ventricular Dyssynchrony,
Left Ventricular Lead Position, and Myocardial
Scar to Predict Long-Term Survival of Ischemic
Heart Failure Patients Undergoing Cardiac
Resynchronization Therapy
Delgado V, van Bommel RJ, Bertini M, et al.
Circulation 2011;123:70–78.
Study Question: Does myocardial scar, left ventricular (LV)
lead position, or dyssynchrony predict response to cardiac
resynchronization therapy (CRT) in heart failure? 
Methods: Echocardiography-derived two-dimensional speckle
tracking with radial strain analysis was used to measure LV
mechanical activation and dyssynchrony prior to CRT ther-
apy in 397 patients with ischemic cardiomyopathy (LV
ejection fraction ≤35%), New York Heart Association class
III-IV heart failure, and a QRS ≥120 ms. LV dyssynchrony
was defined as a delay of ≥130 ms between the anteroseptal
and posterior segments. Strain measures were also used to
define areas of myocardial scar (peak radial strain <16.5%).
The primary endpoint was the composite of heart failure
hospitalization and mortality. 
Results: Mean patient age was 67 ± 10 years, 81% were in
sinus rhythm, and 44% had evidence of LV dyssynchrony.
After a mean 21 months of CRT therapy, 39 patients (10%)
were hospitalized 88 times and 88 (22%) patients died. In
those with radial dyssynchrony, survival (82% vs. 65%) and
survival free of the composite endpoint (75% vs. 63%) were
higher than in those without dyssynchrony. Survival and
survival free of the composite endpoint were also higher in
patients whose LV lead was positioned at the site of latest
mechanical activation and in those whose lead was not posi-
tioned within myocardial scar. Discordant LV lead position
(hazard ratio [HR], 2.1), myocardial scar at the lead (HR,
2.9), and smaller LV radial dyssynchrony were (HR, 0.995)
multivariable correlates of mortality and offered good dis-
crimination for outcome. 
Conclusions: LV dyssynchrony, myocardial scar, and LV lead
position predict outcome following CRT.
Perspective: Identification of subjects who will benefit from
CRT remains challenging. Independent validation in a sepa-
rate cohort of patients, along with an assessment of inter-
and intra-reader correlation of the echocardiography meas-
ures, is warranted. These findings do not apply to those
without an ischemic etiology for heart failure.  
Summary written by: Jennifer Ann Cowger, MD
Interventional Cardiology
Transradial Approach (Left vs Right) and
Procedural Times During Percutaneous Coronary
Procedures: TALENT Study
Sciahbasi A, Romagnoli E, Burzotta F, et al.
Am Heart J 2011;161:172–179.
Study Question: What is the safety and efficacy of the left
radial approach (LRA) compared with right radial approach
(RRA) for coronary procedures? 
Methods: From January 2009 to December 2009, in two hos-
pitals, 1,540 patients were randomized to RRA or LRA
(both 770 patients) for percutaneous coronary procedures.
The primary endpoint was fluoroscopy time for coronary
angiography (CA) and for percutaneous coronary interven-
tion (PCI) evaluated independently. Prespecified subgroup
analyses according to patient age and operator experience
were planned.
Results: In 732 RRA and 735 LRA patients, a CA (diagnos-
tic group) was performed, and in 344 patients each for RRA
and LRA, a PCI was performed. In the diagnostic group,
LRA was associated with significantly lower fluoroscopy
time (149 seconds; interquartile range [IQR], 95-270 sec-
onds) and dose area product fluoroscopy (10.7 Gy cm2;
IQR, 6-20.5 Gy cm2) compared with the RRA (168 sec-
onds; IQR, 110-277 seconds and 12.1 Gy cm2; IQR, 7-23.8
Gy cm2, respectively). In the PCI group, there were no sig-
nificant differences in fluoroscopy time (614 seconds; IQR,
367-1,087 seconds for LRA and 695 seconds; IQR, 415-
1,235 seconds for RRA) and dose area product fluoroscopy
(53.7 Gy cm2; IQR, 29-101 Gy cm2 for LRA and 63.1 Gy
cm2; IQR, 31-119 Gy cm2 for RRA). In subgroup analyses,
the differences between LRA and RRA were confined to
older patients (≥70 years old) and to operators in training. 
Conclusions: The LRA for coronary diagnostic procedures is
associated with lower fluoroscopy time and radiation dose
adsorbed by patients compared with the RRA.
Perspective: The left radial advantage seems to be confined to
operators at the beginning of their learning curve, and more
evident in older patients. The investigators used preshaped
catheters for the transfemoral approach (Judkins curves) for
radial catheterization, and it is possible that these catheters
may reduce the differences between LRAs and RRAs.  
Summary written by: Debabrata Mukherjee, MD
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Noninvasive Cardiology
Critical Appraisal of the Carotid Duplex Consensus
Criteria in the Diagnosis of Carotid Artery Stenosis
AbuRahma AF, Srivastava M, Stone PA, et al.
J Vasc Surg 2011;53:53–59.
Study Question: What is the validity of the 2003 Society of
Radiologists in Ultrasound consensus criteria for diagnosing
carotid artery stenosis? 
Methods: The authors compared the carotid duplex and
angiography results of 376 carotid arteries in 197 patients.
Receiver-operating characteristic (ROC) curves were used to
compare peak systolic velocities (PSVs), end-diastolic veloci-
ties (EDVs) of the internal carotid artery (ICA), and
ICA/common carotid (CCA) ratios in detecting <50%, 50-
69%, and 70-99% stenosis of the ICA.
Results: The consensus criteria for detection of 50-69%
stenosis using a PSV of 125-230 cm/s had a sensitivity of
93%, specificity of 68%, and overall accuracy of 85%. The
consensus defined cut-off of a PSV of >230 cm/s for defin-
ing a >70% stenosis had a sensitivity of 99%, specificity of
86%, and overall accuracy of 95%. Based on ROC, PSV
(area under the curve [AUC] 0.97) was superior to EDV
(AUC 0.94) or ICA/CCA ratio (AUC 0.84) in defining
severity of stenosis. The addition of EDV or ICA/CCA
ratio did not increase the accuracy of PSV in defining
severity of stenosis. The accuracy of detecting 50-69%
stenosis was increased by using an ICA PSV of 140-230
cm/s, with a sensitivity of 94%, specificity of 92%, and
overall accuracy of 92%.
Conclusions: The consensus criteria can be accurately used for
diagnosing ≥70% carotid artery stenosis. 
Perspective: This study suggests that use of these validated
criteria may provide standardization across different labora-
tories, although such validation is probably best obtained
from larger multicentric studies. Further, the accuracy of
duplex while very high, is not 100%, and must be consid-
ered in conjunction with patient symptoms and other
comorbidities (e.g., low cardiac output, aortic stenosis, con-
tralateral occlusion, etc.) that may impact the diagnostic
accuracy of carotid duplex.
Summary written by: Hitinder S. Gurm, MBBS
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The Importance of Population-Wide Sodium
Reduction as a Means to Prevent Cardiovascular
Disease and Stroke: A Call to Action From the
American Heart Association
Appel LJ, Frohlich ED, Hall JE, et al.
Circulation 2011;Jan 13:[Epub ahead of print].
Perspective: The following are 10 points to remember about
sodium reduction: 
1: The risk of cardiovascular disease (CVD), stroke, and end-
stage kidney disease increases progressively throughout the
range of usual blood pressure (BP) starting at a level of
>115/75 mm Hg.
2: Overall, elevated BP is the second leading modifiable cause
of death, accounting for an estimated 395,000 preventable
US deaths in 2005. Worldwide, elevated BP accounts for
54% of stroke and 47% of coronary heart disease events. 
3: The 2020 goal of the American Heart Association is to
improve the cardiovascular health of all Americans by 20%,
and reduce deaths from CVD and stroke by 20%. 
4: Two of the key metrics for ideal cardiovascular health are
a BP of <120/80 mm Hg and sodium consumption of
<1500 mg/d.
5: Excess intake of salt has a major role in the pathogenesis of
elevated BP, and BP-independent effects including promoting
left ventricular hypertrophy and fibrosis in the heart, kidneys,
and arteries.
6: Salt-restricted diets lower the BP in normotensive and
hypertensive persons, especially when salt is reduced by 4600
mg/d (22.7/9.1 mm Hg). The benefit of reduction in salt
intake by 900 mg/d has a greater impact on BP when the
baseline intake is ~2300 mg/d than ~3500 mg/d.
7: An acute increase in sodium intake impairs vascular
endothelial function in young adults with normal BP, and
among middle-aged and older adults with elevated systolic
BP, lower sodium intake is associated with enhanced vascular
endothelial function, independent of BP or other risk factors.
8: US Dietary Guidelines for Americans in 2005 recom-
mend a sodium intake of ~2300 mg/d for all adults and state
that hypertensive individuals, blacks, and middle-aged and
older adults would benefit from reducing sodium intake to
1500 mg/d.
9: A national effort that reduces sodium intake by 1200 mg/d
should result in 60,000 to 120,000 fewer CHD events, 32,000
to 66,000 fewer strokes, 54,000 to 99,000 fewer myocardial
infarctions, and 44,000 to 92,000 fewer deaths, and should
save $10-$24 billion in health care costs annually.
10: Any meaningful strategy to reduce sodium intake popula-
tion-wide must involve the efforts of food manufacturers, food
processors, and restaurant industries, a strategy that is success-
ful in other countries.
Summary written by: Melvyn Rubenfire, MD
JACC, Vol. 57, No. 9, 2011
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Consumption of Added Sugars and Indicators of
Cardiovascular Disease Risk Among US Adolescents
Welsh JA, Sharma A, Cunningham SA, Vos MB.
Circulation 2011;123:249–257.
Study Question: Is consumption of added sugars associated with
risk for cardiovascular disease (CVD) among US adolescents?   
Methods: This cross-sectional study of 2,157 US adolescents
(ages 12-18 years) used data from the National Health and
Nutrition Examination Survey (NHANES), 1999-2004.
Dietary data collected from one 24-hour recall were merged
with information on added sugar content data using the US
Department of Agriculture MyPyramid Equivalents data-
bases. Measures of CVD risk were estimated by added sugar
consumption level (<10%, 10 to <15%, 15 to <20%, 20 to
<25%, 25 to <30%, and >30% of total energy). Multivariate
models were weighted to be representative of the US adoles-
cent population.
Results: In this cohort of 2,157 adolescents, average daily
consumption of added sugars was 21.4% of total daily
energy. Added sugar intake was inversely correlated with
mean high-density lipoprotein (HDL) cholesterol levels.
Among the highest consumers (>30% total energy), HDL
cholesterol levels were 1.28 mmol/L compared with 1.40
mmol/L among the lowest consumers (<10% total energy), a
difference of 9% (p = 0.001). Added sugar was positively
correlated with low-density lipoprotein (LDL) cholesterol (p
trend < 0.01). Among the highest compared to the lowest
consumers, adjusted LDL levels were 2.44 and 2.24
mmol/L. A similar trend was observed for geometric mean
triglycerides (p trend < 0.05). The difference between lowest
and highest consumers of added sugars was 9% in LDL lev-
els (p = 0.08) and 10% in triglyceride levels (p = 0.07). There
was no significant trend in total cholesterol with higher
intake of added sugars. Intake of added sugars and HOMA-
IR measures were positively correlated among overweight
adolescents (p for linear trend < 0.004), but not among nor-
mal weight adolescents. 
Conclusions: Added sugar consumption among US adolescents
is positively associated with CVD risk factors. 
Perspective: This study highlights the importance of a healthy
diet starting at an early age. Improved education and commu-
nity interventions to reduce foods high in added sugars may
assist in modifying dietary practices among adolescents.
Summary written by: Elizabeth A. Jackson, MD
A Randomized Trial of Internet and Telephone
Treatment for Smoking Cessation
Graham AL, Cobb NK, Papandonatos GD, et al.
Arch Intern Med 2011;171:46–53.
Study Question: Does Internet and telephone treatment for
smoking cessation increase quit rates? 
Methods: The Quit Using Internet and Telephone Treatment
(iQUITT) study was a randomized controlled trial, which
compared basic Internet, enhanced Internet, and enhanced
Internet with proactive telephone counseling. QuitNet pro-
vided advice to quit, assistance in setting a quit date,
assessment of motivation, smoking history, and nicotine
dependence, individually tailored information on quitting,
problem solving and skills training, assistance with using
pharmacologic therapies for quitting, and online social sup-
port. The trial was conducted from March 8, 2005, through
November 30, 2008. Current adult US smokers of five or
more cigarettes per day were eligible. The primary outcome
of interest was 30-day abstinence measured at 3, 6, 12, and
18 months after randomization using intent-to-treat analysis.
Results: A total of 2,005 smokers were enrolled. Mean age
was 35.9 years, 51.1% were women, and 86.5% were white.
The follow-up assessment rate at 18 months was 68.2%. At
18 months, the 30-day multiple point prevalence absti-
nence rate across all follow-up intervals was 3.5% for the
basic Internet, 4.5% for the enhanced Internet, and 7.7%
for the enhanced Internet with proactive telephone coun-
seling group. At 18 months, 30-day single point prevalence
abstinence rates were 19.0% for the basic Internet, 17.4%
for the enhanced Internet, and 19.6% for the enhanced
Internet with proactive telephone counseling group, with
no significant difference between groups.
Conclusions: A combined Internet and telephone treatment
outperforms static and dynamic Internet interventions for
smoking cessation. 
Perspective: This well-designed trial exemplifies the novel
aspects of Internet-based interventions for behavioral change.
Although the quit rates were modest, the investigators used
the Internet to reach a broad group of smokers; thus, the
impact of this intervention has potential to be far greater
than the traditional multicenter or single-center trial.
Summary written by: Elizabeth A. Jackson, MD
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